reveal recognition motifs for the MRGPRD GPCR Chunyu Wang ,  Yongfeng Liu ,  Marion Lanier ,   Brian K ductal adenocarcinoma, β-blockers and antihistamines: A clinical trial is needed Jillian G Baker ,  Erica K Sloan ,   Kevin Pfleger ,  Peter J McCormick , Cristina Salmerón ,   Paul A Insel PGxDB: an interactive

K., Gellman, S. H., Pautsch, A., Steyaert, J., Weis, W. I., & Kobilka, B. K. (2011). M., Manglik, A., Hu, J., Hu, K., Eitel, K., Hübner, H., Pardon, E., Valant, C., Sexton, P. I., Garcia, K. C., Wess, J., & Kobilka, B. K. (2013). D., Tworak, A., Watanabe, K., Pardon, E., Steyaert, J., Kandori, H., Katayama, K., Kiser, P. ., & Palczewski, K. (2023).

K., & Jacobson, K. A. (2010). Structure-based discovery of A2A adenosine receptor ligands. K., Bouvier, M., & Babu, M. M. (2023). L., Gregory, K. J., White, P. J., Sexton, P. M., Christopoulos, A., & May, L. T. (2016).

The predictive ability of the model was evaluated by Kaplan-Meier (K-M) survival analysis. K-M analysis of the prognostic model showed that it could differentiate high- and low-risk patients,

Bongers B J , Gorostiola González M , Wang X , van Vlijmen HWT , Jespers W , Gutiérrez-de-Terán H , Ye K

Authors Aurosikha Das, Pulkit K Gupta, Soumendra Rana Tags C5a; C5aR2/C5L2 receptor; lipid bilayer; molecular